Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이규용 | - |
dc.date.accessioned | 2018-03-15T05:15:27Z | - |
dc.date.available | 2018-03-15T05:15:27Z | - |
dc.date.issued | 2014-01 | - |
dc.identifier.citation | NEUROBIOLOGY OF AGING, 권: 35, 호: 6, 페이지: 1255-1274 | en_US |
dc.identifier.issn | 0197-4580 | - |
dc.identifier.issn | 1558-1497 | - |
dc.identifier.uri | http://www.sciencedirect.com/science/article/pii/S019745801300657X?_rdoc=1&_fmt=high&_origin=gateway&_docanchor=&md5=b8429449ccfc9c30159a5f9aeaa92ffb | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/47106 | - |
dc.description.abstract | GV1001 is a 16-amino-acid vaccine peptide derived from the human telomerase reverse transcriptase sequence. We investigated the effects of GV1001 against beta-amyloid (A beta) oligomer-induced neurotoxicity in rat neural stem cells (NSCs). Primary culture NSCs were treated with several concentrations of GV1001 and/or A beta(25-35) oligomer for 48 hours. GV1001 protected NSCs against the A beta(25-35) oligomer in a concentration-dependent manner. A beta(25-35) concentration dependently decreased viability, proliferation, and mobilization of NSCs and GV1001 treatment restored the cells to wild-type levels. A beta(25-35) increased free radical levels in rat NSCs while combined treatment with GV1001 significantly reduced these levels. In addition, GV1001 treatment of A beta(25-35) injured NSCs increased the expression level of survival-related proteins, including mitochondria-associated survival proteins, and decreased the levels of death and inflammation-related proteins, including mitochondria-associated death proteins. Together, these results suggest that GV1001 possesses neuroprotective effects against A beta(25-35) oligomer in NSCs and that these effects are mediated through mimicking the extra-telomeric functions of human telomerase reverse transcriptase, including the induction of cellular proliferation, anti-apoptotic effects, mitochondrial stabilization, and anti-aging and anti-oxidant effects. (C) 2014 Elsevier Inc. All rights reserved. | en_US |
dc.description.sponsorship | This work was supported by a grant (2012R1A1B3000473) from the Korea Research Foundation and the NanoBio R&D Program of the Korea Science and Engineering Foundation, funded by the Ministry of Education, Science and Technology (2007-04717). | en_US |
dc.language.iso | en | en_US |
dc.publisher | ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA | en_US |
dc.subject | Peptide | en_US |
dc.subject | Vaccine | en_US |
dc.subject | GV1001 | en_US |
dc.subject | beta-Amyloid | en_US |
dc.subject | Oligomer | en_US |
dc.subject | Neural stem cells | en_US |
dc.title | The novel vaccine peptide GV1001 effectively blocks beta-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase | en_US |
dc.type | Article | en_US |
dc.relation.volume | 35 | - |
dc.identifier.doi | 10.1016/j.neurobiolaging.2013.12.015 | - |
dc.relation.page | 1255-1274 | - |
dc.relation.journal | NEUROBIOLOGY OF AGING | - |
dc.contributor.googleauthor | Park, Hyun-Hee | - |
dc.contributor.googleauthor | Lee, Kyu-Yong | - |
dc.contributor.googleauthor | Kim, Sang-jae | - |
dc.contributor.googleauthor | Lee, Jessica Woojin | - |
dc.contributor.googleauthor | Choi, Na-Young | - |
dc.contributor.googleauthor | Lee, Eun-Hye | - |
dc.contributor.googleauthor | Lee, Young-Joo | - |
dc.contributor.googleauthor | Lee, Sang-Hun | - |
dc.contributor.googleauthor | Koh, Seong-Ho | - |
dc.relation.code | 2014036568 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | kylee | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.